Research ArticleOriginal Research

Induction of Medication for Opioid Use Disorder in Primary Care

Tristen L. Hall, Douglas H. Fernald, Vivian Jiang, Kristen Curcija, Joseph W. LeMaster, John M. Westfall, Donald E. Nease and Linda Zittleman
The Journal of the American Board of Family Medicine May 2025, 38 (3) 539-550; DOI: https://doi.org/10.3122/jabfm.2024.240317R1

References

  1. 1.↵
    1. Mattson CL,
    2. Tanz LJ,
    3. Quinn K,
    4. Kariisa M,
    5. Patel P,
    6. Davis NL
    . Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States. MMWR Morb Mortal Wkly Rep 2021;70:202–7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Jones CM,
    2. Han B,
    3. Baldwin GT,
    4. Einstein EB,
    5. Compton WM
    . Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open 2023;6:e2327488-e2327488.
    OpenUrl
  3. 3.↵
    1. Spencer MR,
    2. Garnett MF,
    3. Miniño AM
    . Drug overdose deaths in the United States, 2002–2022. NCHS Data Brief 2024;491.
  4. 4.↵
    1. Krawczyk N,
    2. Rivera BD,
    3. Jent V,
    4. Keyes KM,
    5. Jones CM,
    6. Cerdá M
    . Has the treatment gap for opioid use disorder narrowed in the US? A yearly assessment from 2010 to 2019. Int J Drug Policy 2022;110:103786.
    OpenUrlPubMed
  5. 5.↵
    1. Mauro PM,
    2. Gutkind S,
    3. Annunziato EM,
    4. Samples H
    . Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open 2022;5:e223821-e223821.
    OpenUrl
  6. 6.↵
    1. Schoenfeld EM,
    2. Soares WE,
    3. Schaeffer EM,
    4. Gitlin J,
    5. Burke K,
    6. Westafer LM
    . “This is part of emergency medicine now”: A qualitative assessment of emergency clinicians’ facilitators of and barriers to initiating buprenorphine. Acad Emerg Med 2022;29:28–40.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Substance Abuse and Mental Health Services Administration. Waiver Elimination (MAT Act). 2024; Available at: https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act. Accessed June 28, 2024.
  8. 8.↵
    1. Sharma A,
    2. Kelly SM,
    3. Mitchell SG,
    4. Gryczynski J,
    5. O'Grady KE,
    6. Schwartz RP
    . Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep 2017;19:35–8.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Caton L,
    2. Shen H,
    3. Assefa MT,
    4. Fisher T,
    5. McGovern MP
    . Expanding access to medications for opioid use disorder in primary care: an examination of common implementation strategies. Journal of Addiction Research & Therapy 2020;3:72.
  10. 10.↵
    1. Stone EM,
    2. Kennedy-Hendricks A,
    3. Barry CL,
    4. Bachhuber MA,
    5. McGinty EE
    . The role of stigma in US primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend 2021;221:108627.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Peterson LE,
    2. Morgan ZJ,
    3. Borders TF
    . Practice predictors of buprenorphine prescribing by family physicians. J Am Board Fam Med 2020;33:118–23.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Hutchinson E,
    2. Catlin M,
    3. Andrilla CHA,
    4. Baldwin L-M,
    5. Rosenblatt RA
    . Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med 2014;12:128–33.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Andrilla CHA,
    2. Coulthard C,
    3. Larson EH
    . Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med 2017;15:359–62.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Cao SS,
    2. Dunham SI,
    3. Simpson SA
    . Prescribing buprenorphine for opioid use disorders in the ED: a review of best practices, barriers, and future directions. Open Access Emerg Med 2020;12:261–74.
    OpenUrlPubMed
  15. 15.↵
    1. Gardner-Buckshaw SL,
    2. Perzynski AT,
    3. Spieth R,
    4. et al
    . Increasing primary care utilization of medication-assisted treatment (MAT) for opioid use disorder. J Am Board Fam Med 2023;36:251–66.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Carswell N,
    2. Angermaier G,
    3. Castaneda C,
    4. Delgado F
    . Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting. Hosp Pract (1995) 2022;50:251–8.
    OpenUrl
  17. 17.↵
    1. Kermack A,
    2. Flannery M,
    3. Tofighi B,
    4. McNeely J,
    5. Lee JD
    . Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat 2017;74:1–6.
    OpenUrlPubMed
  18. 18.↵
    1. Gunderson EW
    . Buprenorphine induction: a major barrier for physician adoption of office-based opioid dependence treatment. J Addict Med 2011;5:304–5.
    OpenUrlPubMed
  19. 19.↵
    1. Cernasev A,
    2. Hohmeier KC,
    3. Frederick K,
    4. Jasmin H,
    5. Gatwood J
    . A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. Explor Res Clin Soc Pharm 2021;2:100029.
    OpenUrlPubMed
  20. 20.↵
    1. Dickson-Gomez J,
    2. Spector A,
    3. Weeks M,
    4. Galletly C,
    5. McDonald M,
    6. Green Montaque HD
    . “You’re not supposed to be on it forever”: Medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Substance Abuse: Research and Treatment 2022;16:1–10.
    OpenUrl
  21. 21.↵
    Substance Abuse and Mental Health Services Administration. Substance Abuse and Mental Health Services Administration (SAMHSA): Practical Tools for Prescribing and Promoting Buprenorphine in Primary Care Settings. Rockville, MD: National Mental Health and Substance Use Policy Laboratory; 2021.
  22. 22.↵
    1. Martin SA,
    2. Chiodo LM,
    3. Bosse JD,
    4. Wilson A
    . The next stage of buprenorphine care for opioid use disorder. Ann Intern Med 2018;169:628–35.
    OpenUrlPubMed
  23. 23.↵
    1. Lee JD,
    2. Vocci F,
    3. Fiellin DA
    . Unobserved “home” induction onto buprenorphine. J Addict Med 2014;8:299–308.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. DeFlavio JR,
    2. Rolin SA,
    3. Nordstrom BR,
    4. Kazal LA Jr.
    . Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. RRH 2015;15:93–103.
    OpenUrl
  25. 25.↵
    1. Ward KM,
    2. Scheim A,
    3. Wang J,
    4. Cocchiaro B,
    5. Singley K,
    6. Roth AM
    . Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program. Drug Alcohol Depend Rep 2022;3:100055.
    OpenUrlPubMed
  26. 26.↵
    1. Walley AY,
    2. Alperen JK,
    3. Cheng DM,
    4. et al
    . Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med 2008;23:1393–8.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Srivastava A,
    2. Kahan M,
    3. Leece P,
    4. McAndrew A
    . Buprenorphine unobserved “home” induction: a survey of Ontario’s addiction physicians. Addict Sci Clin Pract 2019;14:18.
    OpenUrlPubMed
  28. 28.↵
    Substance Abuse and Mental Health Services Administration. TIP 63: medications for opioid use disorder. 2021; Available at: https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf. Accessed June 30, 2024.
  29. 29.↵
    1. Fernald DH,
    2. Nease DE Jr.,
    3. Westfall JM,
    4. et al
    . A randomized, parallel group, pragmatic comparative-effectiveness trial comparing medication-assisted treatment induction methods in primary care practices: the HOMER study protocol. PLOS One 2023;18:e0290388.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Olfson M,
    2. Zhang V,
    3. Schoenbaum M,
    4. King M
    . Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others: trends in buprenorphine treatment by prescriber specialty-primary care providers, psychiatrists, and addiction medicine specialists. Health Aff (Millwood) 2020;39:984–992.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Britz J,
    2. Chapman D,
    3. Richards A,
    4. et al
    . Bright spot communities: understanding community-level protective factors to improve opioid outcomes in Virginia. Ann Fam Med 2023;21:4060.
    OpenUrlCrossRef
  32. 32.↵
    1. Zittleman L,
    2. Sofie B,
    3. Lutgen C,
    4. et al
    . The odyssey of HOMER: comparative effectiveness research on medication for opioid use disorder during COVID-19. Ann Fam Med 2024;22:444–450.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Glasgow RE,
    2. Harden SM,
    3. Gaglio B,
    4. et al
    . RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health 2019;7:64.
    OpenUrlPubMed
  34. 34.↵
    1. Tong A,
    2. Sainsbury P,
    3. Craig J
    . Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19:349–357.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Creswell JW,
    2. Creswell JD
    . Qualitative Methods. Research Design: Qualitative, Quantitative and Mixed Methods Approaches. Fifth ed. Thousand Oaks, CA: SAGE Publications, Inc.; 2018.
  36. 36.↵
    1. Saunders B,
    2. Sim JA-O,
    3. Kingstone T,
    4. et al
    . Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant 2018;52:1893–1907.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Miles M,
    2. Huberman A,
    3. Saldana J
    . Qualitative data analysis: A methods sourcebook. 4th Ed. ed. Los Angeles, CA: SAGE Publications; 2020.
  38. 38.↵
    1. Miller W,
    2. Crabtree B
    1. Addison R
    . A grounded hermeneutic editing approach. In: Miller W, Crabtree B, eds. Doing qualitative research: Sage Publishers, Thousand Oaks, CA; 1999.
  39. 39.↵
    1. Crabtree BF,
    2. Miller WL
    . A template approach to text analysis: developing and using codebooks. Doing qualitative research. Thousand Oaks, CA: Sage Publications; 1999.
  40. 40.↵
    1. Crabtree B,
    2. Miller W
    1. Borkan J
    . Immersion/crystallization. In: Crabtree B, Miller W, eds. Doing qualitative research. 2 ed. Thousand Oaks, CA: Sage Publications; 1999:179–94.
    OpenUrl
  41. 41.↵
    1. Bridges NC,
    2. Taber R,
    3. Foulds AL,
    4. et al
    . Medications for opioid use disorder in rural primary care practices: patient and provider experiences. J Subst Use Addict Treat 2023;154:209133.
    OpenUrlPubMed
  42. 42.↵
    1. Friedman NL,
    2. Banegas MP
    . Toward addressing social determinants of health: a health care system strategy. TPJ 2018;22.
  43. 43.
    1. de la Vega PB,
    2. Losi S,
    3. Martinez LS,
    4. et al
    . Implementing an EHR-based screening and referral system to address social determinants of health in primary care. Med Care 2019;57 Suppl 6 Suppl 2:S133–S139.
    OpenUrl
  44. 44.
    1. Pinto AD,
    2. Bloch G
    . Framework for building primary care capacity to address the social determinants of health. Can Fam Physician 2017;63:e476–e482.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Andermann A
    , CLEAR Collaboration. Taking action on the social determinants of health in clinical practice: a framework for health professionals. CMAJ 2016;188:E474–E483.
    OpenUrlFREE Full Text
  46. 46.↵
    1. von Klimo MC,
    2. Nolan L,
    3. Corbin M,
    4. et al
    . Physician reluctance to intervene in addiction: a systematic review. JAMA Netw Open 2024;7:e2420837-e2420837.
    OpenUrl
  47. 47.↵
    1. Pytell JD,
    2. Binswanger IA
    . Addressing opioid use disorder in primary care: revisiting core primary care principles to confidently initiate treatment. J Gen Intern Med 2024;39:1749–1750.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords